• Home
  • News
  • Contact
  • #BIOPORT2022
BioportBioport
  • Schedule
  • Sponsors
  • Speakers
  • BioInnovation Challenge
  • Register
  • No menu assigned!

IMV Inc.

  • 0 Shares Share
    0
  • 0

IMV Inc. (formerly known as Immunovaccine Inc.) develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform. DepoVax™ is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system, resulting in a strong, specific and sustained immune response with the capability for single-dose effectiveness. The DepoVax platform possesses impressive flexibility, allowing it to work with a broad range of target antigens in various therapeutic applications. The technology is also commercially scalable, with potential for years of stability and ease of use in the clinic.

  • Previous Project
  • Next Project

CONFERENCE HOST: BIONOVA

#46 1344 Summer Street
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]

Recent News

  • NEWS RELEASE: BioNova Selects Eight Semi-Finalists to Participate in the 12th Annual BioInnovation Challenge August 25, 2022
  • Calling all Early-Stage Health and Life Sciences Companies in Atlantic Canada!  July 5, 2022
  • NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021 November 8, 2021
  • NEWS RELEASE: BioNova Selects Eight Semi-Finalists to Participate in the 11th Annual BioInnovation Challenge August 24, 2021
  • NEWS RELEASE: BioNova to Host the 20th Annual Regional BioPort Conference to Highlight the Innovation and Growth Potential of Health and Life Sciences July 12, 2021

Twitter

© 2016 BioNova

  • Home
  • Schedule
  • Sponsors
  • Speakers
  • BioInnovation Challenge
  • Register
  • News – Original
  • Contact